## **Product** Data Sheet

Inhibitors

Molecular Formula:  $C_{22}H_{22}F_3N_5O_2$ Molecular Weight: 445.44

Target: c-Met/HGFR

Pathway: Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Zgwatinib (SOMG-833) is a potent, selective, and ATP-competitive c-MET inhibitor, with an IC <sub>50</sub> of 0.93 nM against c-MET, over 10,000-fold more potent compared with 19 tyrosine kinases (including c-MET family members and highly homologous kinases). Zgwatinib potently inhibits c-MET-driven cell proliferation. Zgwatinib as a potential candidate agent for c-MET-driven human cancers research <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC50: 0.93 nM (c-MET) <sup>[1]</sup>

## **REFERENCES**

[1]. Zhang, H, et al. SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET-Dependent Neoplastic Effects and Exerts Antitumor Activity. Journal of Pharmacology and Experimental Therapeutics, 350(1), 36-45.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA